We welcome back Nick Levich for our "Ask a Psychedelic Professional" series and as part of our "Ask a Psychedelic Guide" episode.
Similar Posts
Will MAPS IPO? The FIRST American Psychedelic ETF (PSY), New LSD Studies & More
There were LOTS of general news important for the psychedelic industry as a whole and very important study results that will influence some of our favorite stocks such as MindMed (MMED / MNMD / MMQ) and Compass Pathways (CMPS)!
In today’s episode we’ll cover a new American psychedelic ETF which is hitting the market under ticker symbol PSY, some new psilocybin and LSD studies, whether MAPS will turn into a public company and some updates on the California and New York bills we have been covering for a while now.
Enjoy the episode!
Timestamps:
0:00 – Intro
0:40 – The First American Psychedelic ETF (PSY)
5:50 – MAPS Considering An IPO?
12:28 – Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical SSRIs
15:29 – New Study On How LSD Affects The Brain
21:08 – The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD
23:00 – New York Bill Proposes State-Sponsored Psychedelic Research Institute
Links:
New Psychedelic ETF (NYSE : PSY) :
https://www.defianceetfs.com/psy/
https://psychedelicspotlight.com/psy-first-u-s-psychedelic-etf/
Maps Considering An IPO?:
https://www.reddit.com/r/shroomstocks/comments/nqoy0z/maps_considering_ipo/
https://youtu.be/v2HycPpjf6Y
Study Shows Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical Antidepressants:
https://thedalesreport.com/psychedelics/study-shows-psilocybin-assisted-therapy-4-times-more-effective-than-typical-antidepressants/
New Study On How LSD Affects The Brain:
https://www.theguardian.com/science/2021/may/19/acid-test-scientists-show-how-lsd-opens-doors-of-perception
The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD:
https://www.marijuanamoment.net/california-senate-approves-bill-to-legalize-possession-of-psychedelics-like-psilocybin-and-lsd/
New York Bill Proposes State-Sponsored Psychedelic Research Institute:
https://psychedelicspotlight.com/new-york-bill-psychedelic-research-institute/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #MAPS
Psychedelic Business Roundup- Mike Tyson’s New Investment
May 26, 2021-This week’s Psychedelic Business News Round Up’s top…
Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy
Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy
When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.
It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.
Enter Psilera Biosciences.
Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.
PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.
If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.
It is exciting to see Psilera’s scientists working on answering the following questions:
Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Video editing: @themyaholy @Psy_holy
#DMT #DEPRESSION #PSYCHEDELICTHERAPY
“Taking the leap” on Plant Medicines and Psilocybin with Formed NHL Enforcer Riley Cote
In today’s Psychedelic Spotlight episode, we see David Flores and…
BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study
HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).
This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.
In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.
Timestamps:
0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #CMPS #PsychedelicTherapy
Autism on Acid & Psychedelic Symphonies with Aaron Paul Orsini
On this episode, Dennis Walker talks with Aaron Paul Orsini, the co-founder of Autistic Psychedelic Community, author of Autism on Acid, and producer of the recently released, therapy-friendly instrumental music album “Psychedelic Symphonies.”